TrialAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.

Yao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.